Group Gp Lp Column III Buys 18,052 Shares of Surrozen (NASDAQ:SRZN) Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Group Gp Lp Column III purchased 18,052 shares of the stock in a transaction dated Tuesday, January 20th. The shares were bought at an average price of $19.60 per share, for a total transaction of $353,819.20. Following the completion of the acquisition, the insider owned 1,016,658 shares in the company, valued at $19,926,496.80. This represents a 1.81% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Group Gp Lp Column III also recently made the following trade(s):

• On Friday, January 16th, Group Gp Lp Column III acquired 2,562 shares of Surrozen stock. The shares were purchased at an average cost of $20.00 per share, with a total value of $51,240.00.
• On Thursday, January 15th, Group Gp Lp Column III bought 11,893 shares of Surrozen stock. The stock was purchased at an average price of $19.89 per share, for a total transaction of $236,551.77.
• On Wednesday, January 14th, Group Gp Lp Column III bought 5,523 shares of Surrozen stock. The stock was purchased at an average cost of $19.99 per share, for a total transaction of $110,404.77.
• On Tuesday, January 13th, Group Gp Lp Column III purchased 12,470 shares of Surrozen stock. The shares were purchased at an average price of $19.80 per share, with a total value of $246,906.00.
• On Tuesday, January 6th, Group Gp Lp Column III purchased 15,100 shares of Surrozen stock. The stock was purchased at an average cost of $19.89 per share, with a total value of $300,339.00.
• On Friday, December 5th, Group Gp Lp Column III acquired 30,884 shares of Surrozen stock. The stock was purchased at an average price of $19.54 per share, for a total transaction of $603,473.36.
• On Thursday, December 4th, Group Gp Lp Column III purchased 5,266 shares of Surrozen stock. The shares were acquired at an average price of $17.35 per share, for a total transaction of $91,365.10.
• On Thursday, November 13th, Group Gp Lp Column III acquired 315,457 shares of Surrozen stock. The stock was acquired at an average cost of $12.65 per share, with a total value of $3,990,531.05.

Surrozen Price Performance

NASDAQ:SRZN traded down $2.02 during trading hours on Tuesday, reaching $17.98. The company’s stock had a trading volume of 62,608 shares, compared to its average volume of 59,333. The company has a market cap of $154.09 million, a price-to-earnings ratio of -0.80 and a beta of 0.58. Surrozen, Inc. has a one year low of $5.90 and a one year high of $24.94. The business’s 50-day moving average is $18.98 and its 200-day moving average is $14.13.

Surrozen (NASDAQ:SRZN) last released its quarterly earnings results on Friday, November 7th. The company reported ($3.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($2.44). The company had revenue of $0.98 million for the quarter. Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 2,909.10%. On average, sell-side analysts predict that Surrozen, Inc. will post -8.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

SRZN has been the topic of a number of recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Surrozen in a research report on Wednesday, October 8th. Lifesci Capital upgraded shares of Surrozen to a “strong-buy” rating in a report on Thursday, November 13th. Finally, Wall Street Zen upgraded shares of Surrozen to a “sell” rating in a report on Friday, November 28th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Surrozen has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Stempoint Capital LP lifted its stake in shares of Surrozen by 185.1% in the second quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock valued at $6,138,000 after buying an additional 445,713 shares during the period. Braidwell LP acquired a new position in Surrozen in the 2nd quarter valued at approximately $1,252,000. Millennium Management LLC bought a new stake in shares of Surrozen in the 3rd quarter worth approximately $1,414,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Surrozen during the 3rd quarter worth approximately $889,000. Finally, Armistice Capital LLC bought a new stake in shares of Surrozen during the second quarter valued at approximately $536,000. Institutional investors and hedge funds own 66.57% of the company’s stock.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.